OmniAb, Inc. (OABI)
(Delayed Data from NSDQ)
$2.04 USD
+0.09 (4.62%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $2.04 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, OmniAb, Inc. has a market cap of $238.16M, which represents its share price of $1.95 multiplied by its outstanding shares number of 122.14M. As a small-cap company, OABI's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
OABI 2.04 +0.09(4.62%)
Will OABI be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for OABI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OABI
OmniAb, Inc. (OABI) Reports Q1 Loss, Misses Revenue Estimates
OmniAb, Inc. (OABI) Reports Q4 Loss, Tops Revenue Estimates
OABI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Nektar Therapeutics (NKTR) Q4 Earnings Miss Estimates (Revised)
Nektar Therapeutics (NKTR) Q4 Earnings Beat Estimates
Verve Therapeutics (VERV) Reports Q4 Loss, Tops Revenue Estimates
Other News for OABI
OmniAb Inc (OABI) Q2 2025 Earnings Report Preview: What To Expect
OmniAb to Report Second Quarter 2025 Financial Results on August 6 | OABI Stock News
Analysts Offer Insights on Healthcare Companies: Galapagos (GLPG), OmniAb (OABI) and Bristol-Myers Squibb (BMY)
OmniAb Elects Directors at Annual Shareholder Meeting
AbCellera Biologics: The Dilemma Of A Promising Pipeline Alongside Cash Burn